Alicia Arenas

Alicia Arenas

Auto-generated profile, based on publicly available information

Alicia Arenas

Pharmacogenomics and Tumor Biomarkers Group, Institute for Biomedical Research Sols-Morreale (IIBM) CSIC/UAM, Madrid, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2026 in ESMO Open
Verified
Journal Article
Open access
RSRodrigo Sánchez-Bayona
Rodrigo Sánchez-Bayona
JNJ. de Nicolás-Hernández
J. de Nicolás-Hernández
CMCristina Saura Manich
Cristina Saura Manich
MGM. Gion
M. Gion
JCJuan M Cejalvo
Juan M Cejalvo
CRC. Rodriguez-Antona
C. Rodriguez-Antona
Although trastuzumab-deruxtecan (T-DXd) has demonstrated significant efficacy in advanced breast cancer, treatment discontinuation due to adverse events occurs in ∼20% of patients. Pharmacogenetic variants in uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) increase the toxicity risk for other antibody-drug conjugates using topoisomerase I inhibitors, but they remain unexplored for T-DXd. The PROCURE Project is a translational study involving 26 Spanish institutions, investigating the association of germline pharmacogenomic variants with T-DXd toxicity for patients with HER2-positive or HER2-low advanced breast cancer. UGT1A1∗28 genotypes were determined in blood samples, and pharmacogenomic analyses were performed using the clinical data and adverse events extracted from the medical records of the patients. Additionally, stratified Cox models were used to quantify the risk of treatment discontinuation in the different UGT1A1 genotypes. Between July 2022 and March 2024, a total of 292 patients with genetic and clinical information were enrolled in the study. At data cutoff, the median treatment duration with T-DXd was 12.0 months [95% confidence interval (CI) 10.5-14.1]. UGT1A1 genotype distribution among patients was 43.2% wild-type (∗1/∗1), 46.2% heterozygous (∗1/∗28), and 10.3% homozygous (∗28/∗28). No association was observed between UGT1A1 genotypes and the most common T-DXd adverse events. However, poor metabolizers (∗28/∗28) compared with extensive and intermediate metabolizers (∗1/∗1 and ∗1/∗28, respectively) showed a trend toward higher incidence of neutropenia (13.3% versus <6%), as well as a higher incidence of grade ≥3 gastrointestinal toxicity (diarrhea and vomiting). The incidence of drug-induced pneumonitis/interstitial lung disease (ILD) was 11.0% (32/292). No association was observed between UGT1A1 variants and the incidence of pneumonitis/ILD. Patients carrying UGT1A1∗28/∗28 genotype showed a longer treatment duration (HR 0.47, 95% CI 0.23-0.93, P = 0.03) compared with UGT1A1 wild-type patients. In the PROCURE Project, UGT1A1 variants, including the ∗28/∗28 genotype, were not predictive of T-DXd–related adverse events in advanced breast cancer. The project highlights the need to identify alternative biomarkers to optimize toxicity risk stratification and guide personalized treatment strategies.

27 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
JNJavier de Nicolás-Hernández
Javier de Nicolás-Hernández
AAAlicia Arenas
Alicia Arenas
CVCarlos Valdivia
Carlos Valdivia
MSMaría Santos
María Santos
JLJavier Lanillos
Javier Lanillos
Cristina Rodriguez-AntonaCristina Rodriguez-Antona
Cristina Rodriguez-Antona
Purpose: Papillary renal cell carcinoma (pRCC), the second most common subtype of renal cancer, exhibits heterogeneity in molecular features and response to targeted therapies, including antiangiogenic drugs. Discovering molecular biomarkers able to stratify pRCC patients into clinically relevant subgroups and understanding the underlying mechanisms are urgently needed to advance precision medicine. Here, we molecularly dissect a large pRCC series through the expression of the targets of hypoxia inducible factors (HIF), master regulators of angiogenesis, metabolic reprogramming and immune microenvironment. Experimental Design: We merged and analyzed multi-omic and clinical data of 346 patients derived from two pRCC series (TCGA-KIRP and a Spanish metastatic series). Altered pathways and differences in tumor microenvironment were identified through tumor transcriptomic analyses. Tumor metabolome analysis was performed in selected cases. Results: Molecular revision of driver mutations classified 302 patients as pRCC, while uncovering misclassified cases. Analysis of HIF targets gene expression identified a subset of pRCC tumors with increased HIF activity (31%; “HIF-active”). These tumors were characterized by high hypoxia scores, increased angiogenesis, low expression of Krebs cycle genes and mitochondrial activity, high immune infiltration and increased epithelial-mesenchymal transition (P<0.0001; each feature) and they were associated with increased metastasis risk and worse overall survival (P<0.005). Metabolome analyses revealed that HIF-active tumors accumulated L-2-hydroxyglutarate (L-2-HG), an oncometabolite that leads to pseudohypoxia by inhibiting HIF prolyl hydroxylases and preventing HIFα degradation. L-2-HG-accumulation agreed with diminished L2HGDH expression, associated with losing one copy of the gene and low expression of PPARGC1A , which regulates its transcription. Conclusions: HIF-pathway overactivation defines a pseudohypoxic pRCC molecular subgroup characterized by high angiogenesis, immune infiltration and aggressive features. These findings advance our understanding of pRCC diversity, revealing potential clues for the variable response of patients to targeted therapies and paving the way to more personalized pRCC treatments.

1 March 2026 in Genes & Diseases
Verified
Journal Article
Open access
SMSara Mellid
Sara Mellid
ECEduardo Caleiras
Eduardo Caleiras
ÁMÁngel M. Martínez-Montes
Ángel M. Martínez-Montes
AAAlicia Arenas
Alicia Arenas
SJScherezade Jiménez
Scherezade Jiménez
Alberto CasconAlberto Cascon
Alberto Cascon